Compare Ascendis Pharma A/S (ASND) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bank of Nova Scotia — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bank of Nova Scotia trades at $87.3 (market cap $107.21B). The key difference: Bank of Nova Scotia is far larger — about 6× Ascendis Pharma A/S's market cap, and Bank of Nova Scotia pays a 3.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BNS | |
|---|---|---|
Market Cap | $17.74B | $107.21B |
Sector | Health | Financials |
52-Week High | $277.18 | $87.59 |
52-Week Low | $163.32 | $54.50 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BNS trades at $87.59, up 1.78% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.47, exceeding expectations, and maintains a net income margin of 24.86%. Recent news highlights dividend strength and the acquisition of MapleMark Bank to bolster growth. Analyst consensus is 53% buy, with a P/E of 17.15 indicating reasonable valuation.
Outlook is positive due to consistent earnings performance and strategic acquisitions, but risks include high debt levels and economic sensitivity. The stock offers income appeal with a $1.14 dividend, yet investors should monitor credit provisions amid soft economic conditions noted in Q2 2026 reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
